20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T10651 | c-Kit-IN-3 | c-Kit | |
c-Kit-IN-3 is a selective inhibitor of c-KIT kinase with IC50s of 4 nM and 8 nM for c-Kit (wt) and c-Kit (T670I). | |||
T4332 | c-Kit-IN-1 | PDGFR inhibitor 1,DCC-2618 | c-Met/HGFR , c-Kit |
c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM). | |||
T10650 | c-Kit-IN-2 | c-Kit | |
c-Kit-IN-2 is a c-KIT inhibitor (IC50: 82 nM), shows superior antiproliferative activities against all the three GIST cell lines, GIST430, GIST882, and GIST48 (GI50s: 1, 3, and 2 nM). | |||
T19222 | c-Kit-IN-3 maleate | Others | |
c-Kit-IN-3 maleate is a potent and selective c-KIT kinase inhibitor (IC50s: 4 nM, 8 nM for c-KIT wt, and c-KIT T670I). | |||
T19220 | c-Kit-IN-3 hydrochloride | Others | |
c-Kit-IN-3 hydrochloride is a potent and selective c-KIT kinase inhibitor (IC50s: 4 nM, 8 nM for c-KIT wt, and c-KIT T670I). | |||
T19223 | c-Kit-IN-3 tartrate | Others | |
c-Kit-IN-3 tartrate is a potent and selective c-KIT kinase inhibitor (IC50s: 4 nM, 8 nM for c-KIT wt, and c-KIT T670I). | |||
T19221 | c-Kit-IN-3 L-tartrate | Others | |
c-Kit-IN-3 L-tartrate is a potent and selective c-KIT kinase inhibitor (IC50s: 4 nM, 8 nM for c-KIT wt, and c-KIT T670I). | |||
T19219 | c-Kit-IN-3 D-tartrate | Others | |
c-Kit-IN-3 D-tartrate is a potent and selective c-KIT kinase inhibitor (IC50s: 4 nM, 8 nM for c-KIT wt, and c-KIT T670I). | |||
T3452 | ISCK03 | c-Kit | |
ISCK03 is a selective SCF/c-Kit inhibitor. | |||
T5409 | AZD3229 | c-Kit | |
AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. It demonstrates potent single-digit nM growth inhibition across a broad cell panel. | |||
T22256 | c-Kit-IN-5-1 | 3-(2-Aminoquinazolin-6-yl)-4-methyl-1-(4-(oxazol-2-yl)phenyl)pyridin-2(1H)-one,AMG-25,3-(2-aminoquinazolin-6-yl)-4-methyl-1-[4-(1,3-oxazol-2-yl)phenyl]pyridin-2-one | c-Kit |
c-Kit-IN-5-1 (AMG-25) is a novel selective and potent c-Kit inhibitor. | |||
T41003 | KG5 | Raf , FLT , PDGFR , c-Kit | |
KG5 is a dual allosteric inhibitor of PDGFRβ and B-Raf with a Kd of 520 nM and 300 nM for PDGFRβ and PDGFRα. KG5 inhibits FLT3, KIT, and c-Raf with anticancer and antiangiogenic activities. | |||
T22349 | JNJ-38158471 | CS-2660 | VEGFR , c-RET , c-Kit |
JNJ-38158471 (CS-2660), a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, inhibits closely related tyrosine kinases such as Ret and Kit with IC50 of 180 nM and 500 nM. | |||
T9689 | M4205 | c-Kit | |
M4205 is an inhibitor of c-Kit exhibiting high activity on c-Kit mutations in exons 11, 13, 17. | |||
T10652 | Vimseltinib | DCC-3014 | c-Fms , CSF-1R , c-Kit |
Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM). | |||
T2115 | Pexidartinib | PLX-3397 | Apoptosis , c-Fms , FLT , CSF-1R , c-Kit |
Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity. | |||
T5109 | Avapritinib | BLU-285 | PDGFR , c-Kit |
Avapritinib (BLU-285) is a dual inhibitor of the mutant KIT receptor (KIT D816V, IC50: 0.27 nM) and PDGFRα (PDGFRα D842V, IC50: 0.24 nM). | |||
T4320 | Flumatinib | HHGV678 | Bcr-Abl , PDGFR , c-Kit |
Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. | |||
T7945 | SU14813 | VEGFR , PDGFR , c-Kit | |
SU14813 is a multi-receptor tyrosine kinase inhibitor with potent antiangiogenesis and antitumor activity (IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT). | |||
T2624 | OSI-930 | OSI 930 | Apoptosis , c-Fms , Raf , VEGFR , FLT , CSF-1R , Src , c-Kit |
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel growth (angiogenesis) in tumors. |